Quick Answer
GoodRx Holdings, Inc. reported Cash and Equivalents of $261.82 million for fiscal year 2025.
GoodRx Holdings, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $261.82M | -41.6% |
| 2024 | $448.35M | -33.3% |
| 2023 | $672.30M | -11.2% |
| 2022 | $757.16M | -19.5% |
| 2021 | $941.11M | -2.8% |
| 2020 | $968.69M | +3618.6% |
| 2019 | $26.05M | -24.7% |
| 2018 | $34.60M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $273.53M | -35.5% | -2.8% |
| June 30, 2025 | $281.32M | -46.4% | -6.5% |
| March 31, 2025 | $300.98M | -43.6% | -32.9% |
| December 31, 2024 | $448.35M | -33.3% | +5.8% |
| September 30, 2024 | $423.78M | -46.7% | -19.3% |
| June 30, 2024 | $524.90M | -31.1% | -1.6% |
| March 31, 2024 | $533.29M | -29.9% | -20.7% |
| December 31, 2023 | $672.30M | -11.2% | -15.4% |
- GoodRx Holdings, Inc. showed a decrease of -41.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, GoodRx Holdings, Inc.’s cash and equivalents has grown by 656.7% (from $34.60 million to $261.82 million).
- The most recent figure is from GoodRx Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: